Short-term Bactericidal Effect of Contezolid in MAC-PD
Short-term Bactericidal Effect of Contezolid in Mycobacterium Avium Complex Pulmonary Disease
Bin Cao
188 participants
Jul 24, 2025
INTERVENTIONAL
Conditions
Summary
The goal of this clinical trial is to learn if contezolid works to treat mycobacterium avium complex pulmonary disease in adults. It will also learn about the safety of contezolid. The main questions it aims to answer are: Does adding contezolid to standard regimen further decrease the bacterial load in patients' sputum compared with current standard regimen? What medical problems do participants have when taking contezolid along with standard regimen? Researchers will compare standard regimen plus contezolid to standard regimen alone to see if contezolid helps further lower the count of bacteria in patients' sputum. Participants will: Take contezolid and standard regimen (azithromycin, ethambutol and rifampicin) or standard regimen only for 6 months, contezolid is administered every day while other drugs are taken 3 times a week Visit the clinic once every 1 month for checkups and tests.
Eligibility
Plain Language Summary
Simplified for easier understanding
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
contezolid 800mg po q12h for 6 months
azithromycin 500mg po tiw (250mg po tiw if weight below 50kg) for 6 months.
rifampicin 600mg po tiw for 6 months.
ethambutol 25mg/kg po tiw for 6 months.
Locations(3)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07084402